Tuesday, August 16, 2011 (Last Updated: 08/17/2011)
TUESDAY, Aug. 16 (HealthDay News) -- Early endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) is associated with reduced pain and may decrease morphine consumption in patients with painful, inoperable pancreatic adenocarcinoma, according to a study published online Aug. 15 in the Journal of Clinical Oncology.
Jonathan M. Wyse, M.D.C.M., from Centre Hospitalier de l'Universite de Montreal, and colleagues assessed the impact of early EUS-CPN on pain, morphine consumption, quality of life (QOL), and survival in patients with pancreatic cancer, compared with conventional pain management. Of the 580 eligible patients referred for EUS for pancreatic cancer pain between 2006 and 2008, those diagnosed with inoperable adenocarcinoma by EUS and EUS-guided fine-needle aspiration cytology were randomly assigned to early EUS-CPN or conventional pain management (48 to each group). Patients were assessed at one and three months for pain scores, morphine equivalent consumption, and QOL scores.
The investigators found that pain relief in the patients who underwent EUS-CPN was greater at one month and significantly greater at three months. Both groups had similar morphine consumption at one month, but morphine use tended to be lower in the EUS-CPN group at three months. EUS-CPN had no effect on QOL or patient survival.
"Early EUS-CPN reduces pain and may moderate morphine consumption in patients with painful, inoperable pancreatic adenocarcinoma," the authors write.
Hematology & Oncology
Copyright © 2011 HealthDay. All rights reserved.